Failure to achieve co-primary endpoint leaves refractory melanoma patients in limbo

Retrieved on: 2021-04-30 08:26:15

Tags for this article:

Click the tags to see associated articles and topics

Failure to achieve co-primary endpoint leaves refractory melanoma patients in limbo. View article details on hiswai:

Excerpt

Tilsotolimod is designed to work with the ICI Yervoy to synergistically turn 'cold' tumors 'hot' by illuminating cancer cells to the immune system.

Article found on: www.clinicaltrialsarena.com